IT201800003040A1 - Nuovi attivatori dell’enzima SIRT1 per il trattamento delle patologie cardiovascolari e cardiometaboliche - Google Patents

Nuovi attivatori dell’enzima SIRT1 per il trattamento delle patologie cardiovascolari e cardiometaboliche

Info

Publication number
IT201800003040A1
IT201800003040A1 IT102018000003040A IT201800003040A IT201800003040A1 IT 201800003040 A1 IT201800003040 A1 IT 201800003040A1 IT 102018000003040 A IT102018000003040 A IT 102018000003040A IT 201800003040 A IT201800003040 A IT 201800003040A IT 201800003040 A1 IT201800003040 A1 IT 201800003040A1
Authority
IT
Italy
Prior art keywords
cardiovascular
treatment
cardiometabolic diseases
sirt1 enzyme
new activators
Prior art date
Application number
IT102018000003040A
Other languages
English (en)
Inventor
Vincenzo Calderone
Filippo Minutolo
Tiziano Tuccinardi
Lara Testai
Carlotta Granchi
Alma Martelli
Valentina Citi
Lorenzo Gardinal Virginia De
Giulia Lenzi
Francesca Leo
Giulia Malloggi
Original Assignee
Univ Pisa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pisa filed Critical Univ Pisa
Priority to IT102018000003040A priority Critical patent/IT201800003040A1/it
Priority to PCT/IB2019/051489 priority patent/WO2019162911A1/en
Publication of IT201800003040A1 publication Critical patent/IT201800003040A1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/74—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C215/76—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring
    • C07C215/82—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the amino groups further bound to a carbon atom of another six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/01—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and halogen atoms, or nitro or nitroso groups bound to the same carbon skeleton
    • C07C323/09—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and halogen atoms, or nitro or nitroso groups bound to the same carbon skeleton having sulfur atoms of thio groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/257—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings
    • C07C43/295—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT102018000003040A 2018-02-26 2018-02-26 Nuovi attivatori dell’enzima SIRT1 per il trattamento delle patologie cardiovascolari e cardiometaboliche IT201800003040A1 (it)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IT102018000003040A IT201800003040A1 (it) 2018-02-26 2018-02-26 Nuovi attivatori dell’enzima SIRT1 per il trattamento delle patologie cardiovascolari e cardiometaboliche
PCT/IB2019/051489 WO2019162911A1 (en) 2018-02-26 2019-02-25 Fnew activators of sirt1 enzyme for the treatment of cardiovascular and cardiometabolic pathologies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102018000003040A IT201800003040A1 (it) 2018-02-26 2018-02-26 Nuovi attivatori dell’enzima SIRT1 per il trattamento delle patologie cardiovascolari e cardiometaboliche

Publications (1)

Publication Number Publication Date
IT201800003040A1 true IT201800003040A1 (it) 2019-08-26

Family

ID=62167821

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102018000003040A IT201800003040A1 (it) 2018-02-26 2018-02-26 Nuovi attivatori dell’enzima SIRT1 per il trattamento delle patologie cardiovascolari e cardiometaboliche

Country Status (2)

Country Link
IT (1) IT201800003040A1 (it)
WO (1) WO2019162911A1 (it)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024794A1 (en) * 1996-12-03 1998-06-11 Eli Lilly And Company PHENYL GLYOXAMIDES AS sPLA2 INHIBITORS
WO2005003101A2 (en) * 2003-07-02 2005-01-13 Biofocus Discovery Limited Pyrazine and pyridine derivatives as rho kinase inhibitors
WO2006010637A2 (en) * 2004-07-30 2006-02-02 Gpc Biotech Ag Pyridinylamines
WO2009146358A1 (en) * 2008-05-29 2009-12-03 Sirtris Pharmaceuticals, Inc. Imidazopyridine and related analogs as sirtuin modulators

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024794A1 (en) * 1996-12-03 1998-06-11 Eli Lilly And Company PHENYL GLYOXAMIDES AS sPLA2 INHIBITORS
WO2005003101A2 (en) * 2003-07-02 2005-01-13 Biofocus Discovery Limited Pyrazine and pyridine derivatives as rho kinase inhibitors
WO2006010637A2 (en) * 2004-07-30 2006-02-02 Gpc Biotech Ag Pyridinylamines
WO2009146358A1 (en) * 2008-05-29 2009-12-03 Sirtris Pharmaceuticals, Inc. Imidazopyridine and related analogs as sirtuin modulators

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BECERRA-CELY ET AL.: "Insights into Pummerer synthesis of oxazolines", ORG. BIOMOL. CHEM., vol. 14, 2016, pages 8474 - 8485, XP002782527 *
BUTLER D E ET AL: "Novel Pharmacological Activity of a Series of Substituted Pyridines", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 14, no. 7, 1971, pages 575 - 579, XP002321162, ISSN: 0022-2623, DOI: 10.1021/JM00289A005 *
CHEN TAIJIE ET AL: "Cu-mediated selective O-arylation on C-6 substituted pyridin-2-ones", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 54, no. 11, 10 January 2013 (2013-01-10), pages 1401 - 1404, XP028577991, ISSN: 0040-4039, DOI: 10.1016/J.TETLET.2012.12.126 *
DAHLGREN ET AL.: "Virtual screening and optimization yield low-nanomolar inhibitors of the tautomerase activity of Plasmodium falciparum macrophage migration inhibitory factor", J. MED. CHEM., vol. 55, 15 October 2012 (2012-10-15), pages 10148 - 10159, XP002782531 *
JEANNE L. BOLLIGER ET AL: "Access to 2-Aminopyridines - Compounds of Great Biological and Chemical Significance", ADVANCED SYNTHESIS & CATALYSIS, vol. 353, no. 6, 18 April 2011 (2011-04-18), DE, pages 945 - 954, XP055422594, ISSN: 1615-4150, DOI: 10.1002/adsc.201000942 *
KIREN ET AL.: "A benzannulation protocol to prepare substituted aryl amines using a Michael-Aldol reaction of beta-keto sulfones", J. ORG. CHEM., vol. 74, 24 September 2009 (2009-09-24), pages 7781 - 7789, XP002782525 *
LIANG ET AL.: "Palladium-catalyzed C(sp2)-H pyridocarbonylation of N-aryl-2-aminopyridines: dual function of the pyridyl moiety", ORGANIC LETTERS, vol. 16, 7 May 2014 (2014-05-07), pages 2748 - 2751, XP002782530 *
MOR M ET AL: "Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: Synthesis, quantitative structure-activity relationships, and molecular modeling studies", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 47, no. 21, 2 September 2004 (2004-09-02), pages 4998 - 5008, XP002386388, ISSN: 0022-2623, DOI: 10.1021/JM031140X *
SMITH ET AL.: "The reaction of pyrite with diphenyl ether", TETRAHEDRON LETTERS, vol. 25, no. 28, 1984, pages 2949 - 2952, XP002782526 *
SUN T AL.: "Synthesis of N-heterocyclic carbene-Pd(II)-2-methyl-4,5-dihydrooxazole complexes and their application toward highly chemoselective mono-Suzuki-Miyaura coupling of dichlorobenzenes", ASIAN J. ORG. CHEM., vol. 7, 10 February 2018 (2018-02-10), pages 781 - 787, XP002782528 *
TONSON ABRAHAM: "Metalation of 2-methyl-N-phenylbenzamide with n-butyllithium. Formation of N,3-diphenyl-1-isoquinolin-amine by subsequent reaction with benzonitrile", MONATSHEFTE FÜR CHEMIE, vol. 113, 1982, pages 371 - 374, XP002782529 *

Also Published As

Publication number Publication date
WO2019162911A1 (en) 2019-08-29
WO2019162911A8 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
HK1246232A1 (zh) 用於治療非酒精性脂肪肝病的acc抑制劑組合治療
DK3303339T3 (da) Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
SG10201908584SA (en) Fixed Dose Combinations And Formulations Comprising ETC1002 And One Or More Statins And Methods Of Treating Or Reducing The Risk Of Cardiovascular Disease
EP3261671A4 (en) Combination therapy for treatment of coronary artery disease
IL284699A (en) Treatment of diseases associated with enpp1 or enpp3 deficiency
ZA202105111B (en) Pharmaceutical composition for the treatment of pulmonary arterial hypertension
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
IT201700025666A1 (it) Composizione per l’uso nel trattamento dell’ipercolesterolemia e nella prevenzione di patologie cardiovascolari.
DK3290525T3 (da) Fremgangsmåde til screening af lægemiddel og terapeutisk mål der anvendes til behandling af alzheimers sygdom
IT201700085412A1 (it) Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare
IT201700045285A1 (it) Trasduttore microelettromeccanico basato su trincea e metodo di fabbricazione del trasduttore microelettromeccanico
GB201709136D0 (en) New therapeutic uses of enzyme inhibitors
DK3937948T3 (da) Phytoecdysoner og derivater deraf til anvendelse i behandlingen af neuromuskulære sygdomme
IT201800003040A1 (it) Nuovi attivatori dell’enzima SIRT1 per il trattamento delle patologie cardiovascolari e cardiometaboliche
IT201900019391A1 (it) Composizione per la riduzione del rischio cardiovascolare
IT201700111261A1 (it) Composizione per il trattamento delle neuropatie metaboliche e meccaniche
DK3515409T3 (da) Kompleks og sammensætninger til behandling af oftalmologiske og dermatologiske sygdomme
DK3397123T3 (da) Kølende støttepude og fremgangsmåde til fremstilling deraf
CY1123322T1 (el) Φαρμακευτικη συνθεση περιλαμβανουσα μπισοπρολολη και περινδροπριλη
ITUA20163025A1 (it) Composizione per il trattamento della sindrome dell’ovaio policistico
EP3876946A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF VIRGIN DISEASE AND CARDIOPULMONARY DISEASES
IT201700099855A1 (it) Procedimento per la produzione di biomasse microbiche ed il trattamento di siero da latte o altri reflui dell’industria lattiero casearia
IT201700091381A1 (it) Periferica di comando per la simulazione di procedure endoscopiche.